Effectiveness, Treatment Pattern, and Safety of Ranibizumab
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to evaluate the real-world effectiveness, treatment patterns, and safety of Ranibizumab in Korean patients with neovascular age-related macular degeneration (nAMD) that infers positive outcomes.

Adults aged more than 18 years who were either treatment-naive or prior-treated were enrolled and treated with ranibizumab 0.5 mg as per the local label. Outcome measures included mean changes from baseline in visual acuity (VA) and central retinal thickness (CRT), and rate of ocular and non-ocular adverse events (AEs).

--Overall, 367 Korean patients with nAMD (152 treatment-naïve and 215 prior-treated) were enrolled.

--The mean (SD) VA changes from baseline at 1-year were +10.1 and +1.4 Early Treatment Diabetic Retinopathy Study letters, with mean numbers of injections of 5.2 and 3.4 in the treatment-naive and prior-treated groups, respectively.

--VA gains were greater in patients with lower baseline VA, who received a loading dose, and with polypoidal choroidal vasculopathy (PCV).

--Multivariate logistic regression analysis demonstrated younger age, worse baseline VA, and those who received loading dose being associated with higher odds of any gain in VA at 1 year.

--Mean CRT changes from baseline were – 126.7 microm and +10.8 microm in the treatment-naive and prior-treated groups, respectively, with greater reductions observed in patients with PCV.

--Ocular and non-ocular AEs were reported in 8.4% and 10.1% of patients, respectively.

Finally, the LUMINOUS study confirms ranibizumab's real-world efficacy and safety in Korean patients with nAMD; variables such as age, baseline VA, and loading-dose were linked to VA benefit one year after treatment.

Source: https://www.dovepress.com/real-world-effectiveness-treatment-pattern-and-safety-of-ranibizumab-i-peer-reviewed-fulltext-article-OPTH